
Assembly Biosciences is a biopharmaceutical company creating treatments for patients with viral and liver diseases, including herpesviruses.
assemblybio.comCrawled Nov 18, 2026
The expertise to create cures and life-changing treatments
Assembly Biosciences begins a Phase 2 clinical trial for **ABI-6250**, a candidate drug targeting chronic hepatitis delta virus infection. The study evaluates safety and efficacy in patients with the persistent liver disease. The company also releases third-quarter 2026 financial performance updates, though specific metrics are not detailed in the announcement.
Assembly Biosciences initiates a Phase 2 trial testing its oral NTCP inhibitor **ABI-6250** in patients with chronic hepatitis delta virus (HDV) infection. The study assesses safety, drug metabolism, and antiviral effectiveness. Early results are anticipated in late 2027.
Assembly Biosciences reports positive Phase 1a trial results for its experimental therapy ABI-6250, demonstrating safety, tolerability, and target engagement in early testing. The pharmacodynamic analysis of ABI-6250 was highlighted as a *Poster of Distinction* at AASLD The Liver Meeting 2026. Researchers evaluate drug candidates like ABI-6250 to assess their potential for treating liver-related conditions.
Assembly Biosciences secures a 40% profit-sharing agreement with Gilead for the U.S. development and commercialization of its helicase-primase inhibitor program targeting recurrent genital herpes. The deal covers both development costs and future profits from the program. Assembly Bio retains operational control while benefiting financially from the collaboration.
Assembly Biosciences completes a $103.5 million equity raise by issuing 3,924,624 shares at $26.50 each, including underwriters’ full exercise of an option for 566,040 additional shares. The biotech firm develops therapeutics for viral and liver diseases. Proceeds will support its pipeline expansion and clinical programs.
Assembly Biosciences priced a $100 million offering of 3,358,602 shares of common stock at $26.50 per share. Certain investors receive pre-funded warrants to purchase up to 415,000 additional shares instead of stock. The biotech company focuses on developing therapeutics for viral and liver diseases.